 Sorrento Therapeutics Inc NASDAQ: SRNE has entered into an option agreement with The Texas AM University System for exclusive rights to highly potent main protease MPro inhibitors against SARS-CoV-2. This latest agreement bolsters Sorrentos portfolio of preclinical and clinical therapeutic candidates targeting COVID-19. 